Stay updated on IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added, and the prior government funding status notice (v3.4.1) was removed. The core study details and data remain unchanged.
    Difference
    0.4%
    Check dated 2026-02-11T12:22:43.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a government funding/status notice and updated the site version from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T06:41:46.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Glossary toggle and new metadata labels ('Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0') appear on the page, while older labels ('Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4') are removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T06:20:29.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision: v3.3.4 is now listed and Revision: v3.3.3 has been removed.
    Difference
    0.0%
    Check dated 2026-01-14T02:58:27.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    New trial sites have been added in Heidelberg, Amsterdam, Andalusia, Catalonia, Horta de València, and Madrid. Several previously listed locations were removed.
    Difference
    0.7%
    Check dated 2025-12-23T10:41:51.000Z thumbnail image
  7. Check
    92 days ago
    Change Detected
    Summary
    Minor revision: v3.3.2 replaces v3.2.0; this does not alter any study content or page purpose. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-24T17:49:38.000Z thumbnail image

Stay in the know with updates to IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.